Atala Financial Inc Makes New Investment in Bio-Rad Laboratories, Inc. (NYSE:BIO)

Atala Financial Inc purchased a new position in Bio-Rad Laboratories, Inc. (NYSE:BIO) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 266 shares of the medical research company’s stock, valued at approximately $87,000.

Other hedge funds have also added to or reduced their stakes in the company. Venturi Wealth Management LLC lifted its stake in Bio-Rad Laboratories by 2,175.0% in the fourth quarter. Venturi Wealth Management LLC now owns 91 shares of the medical research company’s stock worth $30,000 after purchasing an additional 87 shares during the last quarter. Gladius Capital Management LP bought a new position in shares of Bio-Rad Laboratories during the third quarter valued at about $32,000. Asset Planning Inc bought a new position in shares of Bio-Rad Laboratories during the fourth quarter valued at about $33,000. UMB Bank n.a. raised its stake in shares of Bio-Rad Laboratories by 41.6% during the fourth quarter. UMB Bank n.a. now owns 109 shares of the medical research company’s stock valued at $36,000 after acquiring an additional 32 shares during the last quarter. Finally, Cape Investment Advisory Inc. bought a new position in shares of Bio-Rad Laboratories during the fourth quarter valued at about $38,000. 65.24% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on the stock. Wells Fargo & Company lowered their price objective on shares of Bio-Rad Laboratories from $360.00 to $345.00 and set an “equal weight” rating for the company in a research note on Wednesday, February 12th. StockNews.com downgraded shares of Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a research note on Monday, February 17th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $481.00 price objective on shares of Bio-Rad Laboratories in a research note on Tuesday, January 14th. Three investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $395.20.

Bio-Rad Laboratories Price Performance

BIO stock opened at $255.34 on Friday. Bio-Rad Laboratories, Inc. has a 1 year low of $244.00 and a 1 year high of $387.99. The company has a market cap of $7.15 billion, a P/E ratio of -3.93 and a beta of 0.99. The firm has a 50-day moving average of $311.97 and a 200 day moving average of $327.95. The company has a debt-to-equity ratio of 0.18, a current ratio of 6.48 and a quick ratio of 4.85.

Bio-Rad Laboratories (NYSE:BIO) last released its quarterly earnings results on Thursday, February 13th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.86 by $0.04. Bio-Rad Laboratories had a negative net margin of 71.86% and a positive return on equity of 3.90%. On average, sell-side analysts forecast that Bio-Rad Laboratories, Inc. will post 10.81 EPS for the current year.

Bio-Rad Laboratories Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.